Neoplasms clinical trials

Explore recruiting neoplasms clinical trials.

Recruiting neoplasms studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neoplasms trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients with Neuroendocrine Neoplasms

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A multicenter, open label, two cohort, single arm, phase II study to evaluate the efficacy and safety of the anti-TROP-2 antibody-drug conjugate sacituzumab govitecan in patients with advanced differentiated and anaplastic thyroid neoplasms.

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Selected Advanced Solid Tumors

Spain, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 2, prospective, multi-center intervention trial in patients with acute myeloid leukemia secondary to myeloproliferative neoplasms unfit for intensive chemotherapy investigating a treatment combination including decitabine and venetoclax. ENABLE (vENetoclax plus decitAbine treatment in Blastic phase of myeLoproliferative nEoplasms). AML2420

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AZD2962, an IRAK4 inhibitor, as Monotherapy and in Combination with other Agents, in Participants with Hematologic Neoplasms

Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Safety, pharmacokinetics, and preliminary efficacy of BYON4413 in acute myeloid leukemia and myelodysplastic neoplasms.

Spain, Netherlands, Belgium

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Neoplasms trials by city

Neoplasms in Toronto Neoplasms in Vancouver Neoplasms in Montreal Neoplasms in Calgary Neoplasms in Edmonton Neoplasms in Ottawa Neoplasms in Winnipeg Neoplasms in Quebec City Neoplasms in Hamilton Neoplasms in Kitchener Neoplasms in London Neoplasms in Halifax Neoplasms in New York Neoplasms in Los Angeles Neoplasms in Chicago Neoplasms in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease